Press release
Ischemic Stroke Pipeline Insights Report 2025: Breakthrough Drug Candidates and Strategic R&D Milestones Driving Innovation
Discover the latest drugs and treatment options in the Ischemic Stroke Pipeline. Dive into DelveInsight's comprehensive report today! @ Ischemic Stroke Pipeline Outlook [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Ischemic Stroke Pipeline Report
* Berlin, November 23, 2025, Bayer has reported encouraging topline findings from its global Phase III OCEANIC-STROKE trial evaluating the once-daily, oral FXIa inhibitor asundexian. The investigational therapy achieved both its primary efficacy and safety endpoints, marking a significant milestone in stroke prevention research. According to the results, asundexian 50 mg once daily delivered a meaningful reduction in the risk of ischemic stroke compared with placebo when used alongside antiplatelet therapy in patients who had experienced a non-cardioembolic ischemic stroke or a high-risk ischemic attack. Importantly, the treatment did not lead to an increased rate of ISTH major bleeding, demonstrating a favorable safety profile in comparison to placebo under the same treatment conditions.
* On 21 November 2025, SK Chemicals Co. Ltd announced a Phase IV exploratory Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke.
* On 20 November 2025, Fujian Shengdi Pharmaceutical Co. Ltd conducted a phase II clinical trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke. A study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.
* On 12 November 2025, Basking Biosciences Inc . initiated a study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.
* DelveInsight's Ischemic Stroke pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Ischemic Stroke treatment.
* The leading Ischemic Stroke Companies such as Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Promising Ischemic Stroke Pipeline Therapies such as Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.
Stay ahead with the most recent pipeline outlook for Ischemic Stroke. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Ischemic Stroke Treatment Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Ischemic Stroke Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Ischemic Stroke Pipeline Report also highlights the unmet needs with respect to the development of Ischemic Stroke.
Ischemic Stroke Overview
Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischaemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally. Advances in brain imaging have shifted the definition of ischaemic stroke from a largely clinical determination to a tissue-based classification. Many transient events with full clinical recovery are now classed as stroke based on the identification of permanent tissue injury on MRI. A transient ischemic attack (TIA or mini-stroke) is the same as a stroke but the symptoms only last for a short amount of time. It is a major warning sign of a stroke and should always be taken seriously.
Ischemic Stroke Emerging Drugs Profile
* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
Milvexian (BMS-986177) (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. The drug is being developed by Bristol-Myers Squibb in collaboration with Johnson & Johnson. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke.
* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
* NONO-42: NoNO Inc.
NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase II stage of its development for the treatment of acute ischemic stroke.
* hNPC01: Hopstem Biotechnology
hNPC01 refers to a novel cell therapy utilizing human induced pluripotent stem cell (iPSC)-derived human forebrain neural progenitor cells aimed at treating ischemic stroke. This therapy is particularly significant as it represents the first iPSC-derived product to receive FDA Investigational New Drug (IND) clearance for stroke treatment. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.
Explore groundbreaking therapies and clinical trials in the Ischemic Stroke Pipeline. Access DelveInsight's detailed report now! @ New Ischemic Stroke Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Ischemic Stroke Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
* Ischemic Stroke Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market
Ischemic Stroke Companies
Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Ischemic Stroke Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Ischemic Stroke Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Ischemic Stroke Market Drivers and Barriers [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Ischemic Stroke Pipeline Report
* Coverage- Global
* Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Ischemic Stroke Pipeline Therapies- Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.
* Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Ischemic Stroke Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Ischemic Stroke Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Ischemic Stroke: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ischemic Stroke- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* hNPC01: Hopstem Biotechnology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Ischemic Stroke Key Companies
* Ischemic Stroke Key Products
* Ischemic Stroke- Unmet Needs
* Ischemic Stroke- Market Drivers and Barriers
* Ischemic Stroke- Future Perspectives and Conclusion
* Ischemic Stroke Analyst Views
* Ischemic Stroke Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ischemic-stroke-pipeline-insights-report-2025-breakthrough-drug-candidates-and-strategic-rd-milestones-driving-innovation]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ischemic Stroke Pipeline Insights Report 2025: Breakthrough Drug Candidates and Strategic R&D Milestones Driving Innovation here
News-ID: 4285971 • Views: …
More Releases from ABNewswire
Non Muscle Invasive Bladder Cancer Pipeline Insights Report 2025: Emerging Thera …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Brain Metastases Pipeline Developments Report 2025: Cutting-Edge Therapeutics an …
DelveInsight's, "Brain Metastases Pipeline Insights 2025" report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report…
Dr. Cheng LONG: Innovator and Academic Contributor in the Field of Data Science
In the fast-paced realm of data science and machine learning, professionals with a solid academic background and extensive practical experience are becoming the key drivers of industry progress. Dr. Cheng LONG, currently serving as a Associate Data Scientist at Microsoft, is an outstanding representative of this field. He graduated from Florida State University with a Ph.D. in Statistics, which laid a solid theoretical foundation for his work in data modeling…
ENDRA Life Sciences (NASDAQ: NDRA) Advances "Yield-to-Innovation" Strategy to Ac …
ENDRA Life Sciences (NASDAQ: NDRA) is drawing renewed attention from investors with the rollout of its "Yield-to-Innovation" strategy, a financial and operational framework designed to strengthen long-term growth while advancing the Company's breakthrough TAEUS Registered liver imaging technology.
The model centers on an institutionally managed treasury program engineered to generate stable, non-dilutive returns. Rather than relying solely on traditional equity financing-often expensive and dilutive for early-stage companies-ENDRA's treasury structure provides a…
More Releases for Stroke
Key Trends Reshaping the Acute Ischemic Stroke Diagnosis Market: Companies Revol …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Acute Ischemic Stroke Diagnosis Market Size Growth Forecast: What to Expect by 2025?
The market for diagnosing acute ischemic stroke has seen robust expansion in the last few years. The market size is forecasted to increase from $2.32 billion in 2024 to $2.48 billion in 2025, with a compound…
Stroke Diagnostics Market to Witness Robust Growth Amid Rising Stroke Incidence …
Market Overview
The stroke diagnostics market is estimated to be valued at USD 3.34 Bn in 2025 and is expected to reach USD 5.83 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.
Coherent Market Insights has released a comprehensive new report offering an in-depth analysis of the Stroke Diagnostics Market from 2025 to 2032. This study provides reliable global and regional projections, helping…
Key Trends Shaping the Future Acute Ischemic Stroke Diagnosis Market From 2025-2 …
Which drivers are expected to have the greatest impact on the over the acute ischemic stroke diagnosis market's growth?
The acute ischemic stroke diagnosis market is predicted to expand due to the growing number of acute ischemic stroke incidents. Acute ischemic stroke is a serious health emergency caused by inadequate blood flow to the brain, leading to brain cell damage. Prompt detection of acute ischemic stroke can assist in treatment, minimize…
Ischemic Stroke Aspiration Systems Market: Advancing Stroke Treatment with Innov …
Introduction
The ischemic stroke aspiration systems market is undergoing remarkable growth, driven by technological innovations and increasing awareness of advanced treatment options for stroke management. Ischemic stroke, the most common type of stroke, occurs when blood flow to a part of the brain is blocked, often due to a blood clot. This obstruction can lead to significant brain damage, disability, and even death if not treated swiftly. Aspiration systems, a vital…
Stroke Management Market Size To Reach USD 36.75 Billion, Globally, By 2023 | Di …
Asia-Pacific is expected to grow with the highest market share during the analysis period and would provide high opportunities for the market players.
The global stroke management market was valued at $22,581 million in 2016, and is estimated to reach $36,756 million by 2023, growing at a CAGR of 7.1% from 2017 to 2023. The diagnostics segment held more than five-seventh share of the total market in 2016.
Download Free Report Sample…
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to…
